HC Wainwright reiterated their buy rating on shares of Alimera Sciences (NASDAQ:ALIM) in a research report report published on Monday. They currently have a $5.00 price target on the biopharmaceutical company’s stock.
Several other equities analysts have also weighed in on the stock. Cowen reiterated a buy rating on shares of Alimera Sciences in a report on Thursday, November 2nd. Zacks Investment Research lowered shares of Alimera Sciences from a hold rating to a sell rating in a report on Monday, November 27th. Finally, ValuEngine upgraded shares of Alimera Sciences from a strong sell rating to a sell rating in a report on Monday, November 27th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. Alimera Sciences currently has a consensus rating of Hold and an average price target of $3.38.
Alimera Sciences (NASDAQ ALIM) traded down $0.04 during trading hours on Monday, reaching $1.16. 323,200 shares of the company’s stock traded hands, compared to its average volume of 190,943. The company has a quick ratio of 4.65, a current ratio of 4.84 and a debt-to-equity ratio of -0.71. The firm has a market cap of $84.36, a price-to-earnings ratio of -3.74 and a beta of 2.15. Alimera Sciences has a 12 month low of $1.11 and a 12 month high of $1.72.
In other news, CEO C. Daniel Myers sold 52,900 shares of the company’s stock in a transaction that occurred on Wednesday, January 17th. The shares were sold at an average price of $1.23, for a total value of $65,067.00. Following the transaction, the chief executive officer now directly owns 154,411 shares in the company, valued at approximately $189,925.53. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Philip Ashman sold 25,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $1.23, for a total transaction of $31,365.00. Following the completion of the transaction, the senior vice president now owns 38,250 shares in the company, valued at $47,047.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 184,704 shares of company stock worth $224,432. Company insiders own 14.70% of the company’s stock.
A hedge fund recently raised its stake in Alimera Sciences stock. PNC Financial Services Group Inc. lifted its stake in Alimera Sciences, Inc. (NASDAQ:ALIM) by 24.3% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 180,300 shares of the biopharmaceutical company’s stock after acquiring an additional 35,200 shares during the quarter. PNC Financial Services Group Inc. owned 0.28% of Alimera Sciences worth $251,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 41.77% of the company’s stock.
WARNING: “HC Wainwright Reiterates “Buy” Rating for Alimera Sciences (ALIM)” was originally published by BBNS and is the property of of BBNS. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://baseballnewssource.com/markets/hc-wainwright-reiterates-buy-rating-for-alimera-sciences-alim/1860685.html.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.